Skip to main content

Table 1 Demographic and clinical characteristics for patient cohorts based on lasmiditan dosing pattern

From: Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

Lasmiditan dosing summarya

100 mg (continuous) n = 209

50 mg/100 mg n = 90

100 mg/200 mg n = 136

50 mg/100 mg/ 200 mg n = 6

Totalb

N = 445

Total number of lasmiditan doses administered

18.7 (18.08)

19.5 (16.42)

21.0 (16.28)

20.3 (8.71)

19.5 (17.09)

Lasmiditan doses per month

1.7 (1.34)

1.6 (1.22)

1.8 (1.23)

1.9 (1.41)

1.7 (1.28)

Last dose in double-blind period,

n (%)c

 Placebo

35 (43.8)

14 (17.5)

28 (35.0)

1 (1.3)

80 (100)

 50 mg

42 (48.3)

23 (26.4)

21 (24.1)

1 (1.1)

87 (100)

 100 mg

66 (45.2)

28 (19.2)

50 (34.2)

2 (1.4)

146 (100)

 200 mg

66 (50.0)

25 (18.9)

37 (28.0)

2 (1.5)

132 (100)

Modal dosed

 50 mg

0

52 (57.8)

0

3 (50.0)

57 (12.8)

 100 mg

209 (100)

38 (42.2)

43 (31.6)

3 (50.0)

293 (65.8)

 200 mg

0

0

93 (68.4)

0

94 (21.1)

 Completed, n (%)

144 (68.9)

72 (80.0)

98 (72.1)

5 (83.3)

321 (72.1)

Demographics and clinical characteristicsa

100 mg (continuous) n = 209

50 mg/100 mg n = 90

100 mg/200 mg n = 136

50 mg/100 mg/ 200 mg n = 6

Totalb

N = 445

Age, years

41.5 (12.7)

41.1 (10.9)

45.3 (11.0)

42.5 (8.4)

42.5 (11.9)

Sex, female, n, (%)

181 (86.6)

82 (91.1)

112 (82.4)

5 (83.3)

383 (86.1)

Body weight, kg

76.5 (18.1)

74.9 (18.3)

81.0 (21.6)

79.0 (17.3)

77.5 (19.3)

Migraine history, years

16.1 (12.1)

19.5 (12.5)

21.2 (13.2)

14.8 (12.0)

18.3 (12.7)

Migraine attacks/month in the 3 months prior to study baseline

5.0 (1.6)

5.1 (1.5)

5.0 (1.5)

4.8 (1.5)

5.0 (1.5)

Migraine, aura status, n (%)

 With aura

45 (21.5)

28 (31.1)

24 (17.6)

0 (0.0)

98 (22.0)

 Without aura

121 (57.9)

44 (48.9)

79 (58.1)

5 (83.3)

251 (56.4)

 With and without aura

43 (20.6)

18 (20.0)

33 (24.3)

1 (16.7)

96 (21.6)

 Use of migraine preventive during study, n (%)

67 (32.1)

29 (32.2)

41 (30.1)

2 (33.3)

140 (31.5)

 Triptan experience, n (%)

133 (63.6)

64 (71.1)

97 (71.3)

6 (100.0)

302 (67.9)

MIDAS Total Score

 Baseline (V1)

25.8 (15.36)

31.4 (20.73)

30.4 (18.61)

18.8 (5.81)

28.4 (17.73)

 Last visit (V11 EoS)

12.2 (15.04)

15.2 (14.88)

20.3 (31.51)

12.0 (6.28)

15.3 (21.64)

MIDAS Headache Days

 Baseline (V1)

15.7 (8.36)

15.8 (10.51)

18.2 (11.56)

17.8 (5.45)

16.5 (9.92)

 Last visit (V11 EoS)

8.9 (9.40)

10.3 (10.12)

13.2 (14.91)

14.6 (23.92)

10.6 (11.90)

MIDAS Average Pain Severity

 Baseline (V1)

7.7 (1.54)

7.2 (1.74)

7.3 (1.74)

7.0 (2.24)

7.5 (1.67)

 Last visit (V11 EoS)

6.1 (2.35)

6.1 (2.07)

6.4 (1.89)

5.6 (3.36)

6.2 (2.17)

MSQ Total Score

 OLE baseline (V6)

60.5 (17.54)

64.4 (13.58)

61.4 (16.37)

70.1 (10.58))

61.9 (16.31)

 Last visit (V11 EoS)

73.2 (18.84)

75.5 (17.42)

71.3 (17.62)

67.1 (11.20)

73.2 (18.10)

MSQ Role Function Restrictive

 OLE baseline (V6)

54.1 (17.70)

57.6 (14.18)

54.7 (17.52)

60.1 (16.60)

55.3 (16.91)

 Last visit (V11 EoS)

68.3 (20.61)

70.6 (18.25)

65.6 (19.13)

59.4 (14.48)

68.0 (19.65)

MSQ Role Function Preventive

 OLE baseline (V6)

67.5 (21.29)

71.6 (15.15)

68.6 (18.61)

88.0 (11.51)

69.1 (19.21)

 Last visit (V11 EoS)

77.9 (18.75)

81.5 (16.99)

77.7 (17.20)

76.0 (18.84)

78.7 (17.89)

MSQ Emotional Function

 OLE baseline (V6)

66.9 (24.56)

70.7 (20.97)

67.4 (22.45)

69.3 (14.6`)

68.1 (23.01)

 Last visit (V11 EoS)

78.4 (21.10)

79.0 (22.58)

76.3 (21.45)

73.3 (9.43)

77.9 (21.37)

 mTOQ-6 (V2 Baseline)e

4.8 (2.55)

4.6 (2.48)

4.3 (2.57)

4.8 (2.95)

4.6 (2.55)

PGIC-MHC n (%)

 Very much better

19 (9.1)

11 (12.2)

19 (14.0)

1 (16.7)

50 (11.2)

 Much better

53 (25.4)

11 (12.2)

19 (14.0)

0

83 (18.7)

 A little better

46 (22.0)

25 (27.8)

20 (14.7)

1 (16.7)

92 (20.7)

 No change

58 (27.8)

33 (36.7)

59 (43.4)

4 (66.7)

157 (35.3)

 A little worse

7 (3.4)

3 (3.3)

10 (7.4)

0

20 (4.5)

 Much worse

1 (0.5)

1 (1.1)

2 (1.5)

0

4 (0.9)

 Very much worse

0

1 (1.1)

0

0

1 (0.2)

  1. AE adverse event, EoS end of study, MIDAS Migraine Disability Assessment, MSQ Migraine-Specific Quality of Life Questionnaire, mTOQ-6 Migraine Treatment Optimization Questionnaire, PGIC-MHC Patient Global Impression of Change – Migraine Headache Condition, V visit
  2. aPer study design, visits 1 and 2 represent baseline visits in the double-blind portion of the study whereas visit 6 corresponds to the OLE baseline visit. Mean (SD) shown unless otherwise indicated
  3. bThe total population includes 4 participants who did not administer 100 mg during the OLE and are not represented within any of the 4 cohorts. Data are summarized based on non-missing values at each corresponding time point
  4. cThe proportion of patients taking each of the treatments as their last dose in the double-blind study was calculated using the number of patients in each treatment group as the denominator
  5. dFor modal dose, the proportion of patients with each dose level as a modal dose was calculated using the number of patients in the dosing cohort as the denominator
  6. eData are for current triptan users only
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us